| Literature DB >> 16971205 |
John H Heinzerling1, Sergio Huerta.
Abstract
Avastin (Bevacizumab) is a recently developed monoclonal antibody against vascular endothelial growth factor (VEGF) receptor that increases survival in patients with metastatic colorectal cancer. Bowel perforation is a known risk factor of unknown etiology associated with the use of Avastin. In this report, the incidence, risk factors, typical presentation, and management of patients with this complication is described.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16971205 DOI： 10.1016/j.cursur.2006.06.002
Source DB: PubMed Journal: Curr Surg ISSN： 0149-7944